INFO:

Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses the use of BTK degraders for patients with chronic lymphocytic leukemia (CLL) and low-grade lymphomas. Dr El-Sharkawi highlights the mechanism of action of these agents, which halt BTK enzymatic function and degrade the protein. An ongoing Phase I trial (NCT05131022) is evaluating the safety, tolerability, and preliminary efficacy of oral BTK degrader NX-5948 in adult patients with relapsed/refractory (R/R) B-cell malignancies, and results have thus far shown promise, with limited cases of treatment-related adverse events. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.